U.S. stock market update: ProKidney down 11.33%

U.S. Stock Market Midday Update ProKidney fell 11.33%, with increased trading volume. Based on recent important news: On July 27, a retail investor surge led to a spike in small-cap stock trading volume, affecting ProKidney's stock price, which dropped 11.33%. On July 26, global investor interest in the U.S. market declined, impacting the stock prices of companies like ProKidney. On July 28, changes in the housing market affected investor confidence, putting pressure on ProKidney's stock price. Stocks with High Trading Volume in the Industry Sarepta Therapeutics rose 20.78%, with increased trading volume. Based on recent important news: On July 29, the FDA recommended lifting the hold on Sarepta's Elevidys drug, causing the stock price to rise by 38%. On July 29, JP Morgan upgraded Sarepta's rating from underweight to neutral, believing the FDA's decision is a clear positive. On July 28, Barclays downgraded Sarepta's rating to underweight due to regulatory updates. AbbVie rose 1.79%, with increased trading volume. Based on recent important news: On July 29, AbbVie submitted a new drug application for the combination treatment of Venclexta and Acalabrutinib for CLL, with the market optimistic about its prospects, leading to a stock price increase. On July 29, Eli Lilly's Jaypirca outperformed AbbVie's Imbruvica in CLL/SLL trials, potentially putting pressure on the latter's market share. On July 28, AbbVie's Skyrizi and Rinvoq exceeded expectations, driving company performance growth and boosting investor confidence. Iklisys fell 16.31%, with increased trading volume. Based on recent important news: On July 29, Iklisys's second-quarter financial report fell short of expectations, causing the stock price to drop about 12% in after-hours trading. The report showed that non-GAAP earnings per share fell from $0.84 in the same period last year to $0.75, with total revenue declining approximately 11% year-over-year. On July 29, Morgan Stanley lowered Iklisys's target price from $48 to $46, reflecting market concerns about its future growth. On July 29, Iklisys announced it would no longer advance zanzalintinib in the Phase III trial for head and neck squamous cell carcinoma due to poor Phase II data and intense market competition. Stocks with High Market Capitalization in the Industry Amgen rose 0.81%, with a market capitalization of $163.3 billion and increased trading volume. Based on recent key news: On July 28, Amgen was included in the Dow Jones Dividend Stock Purchase List, highlighting its dividend attractiveness and driving the stock price up by 0.81% On July 29, market analysts maintained a hold rating on Amgen, believing there are better investment options, which limited further increases in the stock price. On July 28, Amgen was seeking its next breakthrough drug, showcasing its strong R&D pipeline, which boosted investor confidence